A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
Completed
GlaxoSmithKline
Phase 3
2006-12-01
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient,
early-intervention evaluation of subjects who have migraine with or without aura and who
discontinued use of short acting triptan(s) within the past year due to non-response or
intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each
attack; one attack will be treated with one tablet of the Combination Product (sumatriptan
succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover
design). [Study 2 of 2]
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Completed
GlaxoSmithKline
Phase 3
2006-11-01
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient,
early-intervention evaluation of subjects who have migraine with or without aura and who
discontinued use of short acting triptan(s) within the past year due to non-response or
intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each
attack; one attack will be treated with one tablet of the Combination Product (sumatriptan
succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover
design). [Study 1 of 2]
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Completed
AstraZeneca
Phase 3
2003-09-01
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig)
nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a
3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
